

# Jeffrey A Tice

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7112540/publications.pdf>

Version: 2024-02-01

68  
papers

4,649  
citations

172457

29  
h-index

138484

58  
g-index

70  
all docs

70  
docs citations

70  
times ranked

5637  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model. <i>Annals of Internal Medicine</i> , 2008, 148, 337.	3.9	450
2	Gastric Banding or Bypass? A Systematic Review Comparing the Two Most Popular Bariatric Procedures. <i>American Journal of Medicine</i> , 2008, 121, 885-893.	1.5	407
3	Prospective Breast Cancer Risk Prediction Model for Women Undergoing Screening Mammography. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1204-1214.	6.3	399
4	Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 743.	7.4	286
5	Phytoestrogen Supplements for the Treatment of Hot Flashes: The Isoflavone Clover Extract (ICE) Study. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 207.	7.4	230
6	Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk. <i>Journal of the National Cancer Institute</i> , 2009, 101, 384-398.	6.3	226
7	Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population. <i>Breast Cancer Research and Treatment</i> , 2005, 94, 115-122.	2.5	219
8	Identifying Women With Dense Breasts at High Risk for Interval Cancer. <i>Annals of Internal Medicine</i> , 2015, 162, 673-681.	3.9	215
9	The Contributions of Breast Density and Common Genetic Variation to Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	6.3	174
10	Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw290.	6.3	171
11	Breast Density and Benign Breast Disease: Risk Assessment to Identify Women at High Risk of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3137-3143.	1.6	170
12	Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 748.	7.4	130
13	Breast cancer risk prediction using a clinical risk model and polygenic risk score. <i>Breast Cancer Research and Treatment</i> , 2016, 159, 513-525.	2.5	129
14	Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. <i>JAMA Internal Medicine</i> , 2016, 176, 65.	5.1	118
15	Benign Breast Disease, Mammographic Breast Density, and the Risk of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1043-1049.	6.3	99
16	Relation of Serum Ascorbic Acid to Mortality Among US Adults. <i>Journal of the American College of Nutrition</i> , 2001, 20, 255-263.	1.8	86
17	The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women. <i>American Journal of Medicine</i> , 2003, 114, 199-205.	1.5	82
18	Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma. <i>JAMA Network Open</i> , 2019, 2, e190035.	5.9	72

#	ARTICLE	IF	CITATIONS
19	Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia. <i>JAMA Pediatrics</i> , 2018, 172, 1161.	6.2	69
20	Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 220-225.	1.0	67
21	Risk Factors for Mortality in Middle-aged Women. <i>Archives of Internal Medicine</i> , 2006, 166, 2469.	3.8	59
22	Nipple Aspirate Fluid Cytology and the Gail Model for Breast Cancer Risk Assessment in a Screening Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 324-328.	2.5	58
23	Estrogen metabolism and breast cancer risk among postmenopausal women: a case-cohort study within B~FIT. <i>Carcinogenesis</i> , 2014, 35, 346-355.	2.8	57
24	Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw276.	6.3	55
25	Validation of the breast cancer surveillance consortium model of breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 519-523.	2.5	55
26	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels. <i>JAMA Internal Medicine</i> , 2016, 176, 107.	5.1	41
27	Breast Cancer Population Attributable Risk Proportions Associated with Body Mass Index and Breast Density by Race/Ethnicity and Menopausal Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2048-2056.	2.5	41
28	Estrogen Metabolism and Risk of Postmenopausal Endometrial and Ovarian Cancer: the B~FIT Cohort. <i>Hormones and Cancer</i> , 2016, 7, 49-64.	4.9	39
29	Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. <i>JAMA Internal Medicine</i> , 2018, 178, 494.	5.1	36
30	One versus Two Breast Density Measures to Predict 5- and 10-Year Breast Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 889-897.	2.5	30
31	Effectiveness and Value of Integrating Behavioral Health Into Primary Care. <i>JAMA Internal Medicine</i> , 2016, 176, 691.	5.1	30
32	The Effect of Change in Body Mass Index on Volumetric Measures of Mammographic Density. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1724-1730.	2.5	26
33	Impact of a primary care based intervention on breast cancer knowledge, risk perception and concern: A randomized, controlled trial. <i>Breast</i> , 2015, 24, 758-766.	2.2	25
34	Screening and Prevention of Breast Cancer in Primary Care. <i>Primary Care - Clinics in Office Practice</i> , 2009, 36, 533-558.	1.6	24
35	Association of Circulating Progesterone With Breast Cancer Risk Among Postmenopausal Women. <i>JAMA Network Open</i> , 2020, 3, e203645.	5.9	23
36	Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 603-612.	2.5	22

#	ARTICLE	IF	CITATIONS
37	Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. JAMA Network Open, 2022, 5, e222440.	5.9	21
38	Introduction. Journal of General Internal Medicine, 2008, 23, 1-1.	2.6	20
39	Estrogen Metabolites Are Not Associated with Colorectal Cancer Risk in Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1419-1422.	2.5	18
40	Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population. Journal of the National Cancer Institute, 2022, 114, 676-685.	6.3	18
41	The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir for Chronic Hepatitis C Virus Infection. JAMA Internal Medicine, 2014, 174, 1170.	5.1	17
42	Medications for Primary Prevention of Breast Cancer. JAMA - Journal of the American Medical Association, 2020, 324, 291.	7.4	17
43	Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention. PLoS ONE, 2017, 12, e0168601.	2.5	16
44	Vitamin D Does Not Prevent Cancer or Cardiovascular Disease: The VITAL Trial. Journal of General Internal Medicine, 2020, , 1.	2.6	14
45	Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial. Npj Breast Cancer, 2021, 7, 78.	5.2	12
46	Full-field digital mammography compared with screen-film mammography in the detection of breast cancer: rays of light through DMIST or more fog?. Breast Cancer Research and Treatment, 2008, 107, 157-165.	2.5	11
47	The Cost-Effectiveness of Belimumab and Voclosporin for Patients with Lupus Nephritis in the United States. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 385-394.	4.5	11
48	Comparing Mammographic Density Assessed by Digital Breast Tomosynthesis or Digital Mammography: The Breast Cancer Surveillance Consortium. Radiology, 2021, , 204579.	7.3	10
49	Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1. JAMA Internal Medicine, 2015, 175, 1559.	5.1	9
50	The Vital Amines: Too Much of a Good Thing?. Archives of Internal Medicine, 2010, 170, 1631-3.	3.8	5
51	An Intervention Tool to Increase Patientâ€“Physician Discussion of Lifestyle Risk Factors for Breast Cancer. Journal of Women's Health, 2019, 28, 1468-1475.	3.3	5
52	The effectiveness and value of novel treatments for cystic fibrosis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 276-280.	0.9	4
53	Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry. Npj Breast Cancer, 2021, 7, 102.	5.2	4
54	Supplemental Breast Cancer Screening: A Density Conundrum. Journal of General Internal Medicine, 2017, 32, 593-594.	2.6	3

#	ARTICLE	IF	CITATIONS
55	Acceptability of an mHealth breast cancer risk-reduction intervention promoting risk assessment, education, and discussion of risk in the primary care setting. MHealth, 2021, 7, 0-0.	1.6	3
56	Endogenous Progestogens and Colorectal Cancer Risk among Postmenopausal Women. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1100-1105.	2.5	3
57	Association of Endogenous Pregnenolone, Progesterone, and Related Metabolites with Risk of Endometrial and Ovarian Cancers in Postmenopausal Women: The B <sub>2</sub> FIT Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2030-2037.	2.5	2
58	The effectiveness and value of belimumab and voclosporin for lupus nephritis. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 1495-1499.	0.9	2
59	The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 528-532.	0.9	1
60	Abstract 589: Circulating progesterone is associated with increased postmenopausal breast cancer risk: B <sub>2</sub> FIT cohort. , 2019, , .		1
61	Cost-effectiveness of Homocysteine-Lowering Therapy to Prevent Coronary Heart Disease—Reply. JAMA - Journal of the American Medical Association, 2002, 287, 191.	7.4	0
62	Mammographic density as a marker of breast cancer risk?. Current Breast Cancer Reports, 2009, 1, 175-180.	1.0	0
63	Screening for Breast Cancer in Women With Dense Breasts. , 2016, , 241-263.		0
64	Abstract B86: Estrogen metabolism and postmenopausal breast cancer risk in the B <sub>2</sub> FIT cohort. Cancer Prevention Research, 2012, 5, B86-B86.	1.5	0
65	Abstract 940: The contribution of common breast cancer susceptibility loci to the breast density and breast cancer association and the Breast Cancer Surveillance Consortium (BCSC) risk model. , 2014, , .		0
66	Abstract 1603: Estrogen metabolites and colorectal cancer risk in postmenopausal women in the Breast and Bone Follow-up to the Fracture Intervention Trial (B <sub>2</sub> FIT). , 2014, , .		0
67	Abstract 2359: Endogenous progestogens and colorectal cancer risk among postmenopausal women. , 2020, , .		0
68	The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 528-532.	0.9	0